Main Article

Aureon Laboratories (Yonkers, NY) is betting on the powerful combination of predictive pathology and personalized medicine to advance clinical laboratory medicine. Although founded in 2001, the company is only now ramping up its commercial activity by applying "systems pathology" to develop predictive clinical tests for cancer, as well as to facilitate biopharmaceutical research and development.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

March 2007 - Table of Contents

LIR March 2007 (full PDF issue)

Quest Buys POC Testmaker HemoCue for $420m

BREAKING NEWS: BioReference Reaches Accord With NJ’s Horizon

ASCP Survey Finds Labs Lack Confidence in Emergency Preparedness

NeoGenomics Gets CLIA Certification for New West Coast Lab

Aureon Labs Combines Predictive Pathology, Personalized Medicine

Selecting Strategic Test Menus for Molecular Diagnostic Laboratories

Washington Hospital Center Labs Get ‘LEAN’

PRL Establishes Regional Collaboration With Kansas Biotech Group

Lab Stocks Rise 6% Led by Monogram

See You at Outreach ‘07